Colony Stimulating Factor Treatment for Demyelinating CNS Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelinating central nervous system diseases like multiple sclerosis are ineffective in reducing pre-existing disability and have limited clinical efficacy, with existing immunomodulatory agents only providing partial relief and no effective solution for immune-mediated conditions.
Innovation Solution
Administration of colony stimulating factors, specifically GM-CSF, to treat demyelinating central nervous system diseases, which stimulates hematopoietic cell proliferation and modulates immune responses, potentially offering therapeutic benefits beyond traditional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunomodulatory agents (interferons, glatiramer acetate) are used to treat multiple sclerosis, then inflammatory activity in the central nervous system decreases, but clinical effectiveness is limited to 30-50% reduction in disease relapses and progressive disability with no effect on pre-existing disability
Solution Approach 1:
The patent applies parameter changes by switching from traditional immunomodulatory agents (interferons, glatiramer acetate) to colony stimulating factors (CSFs) with different molecular structures and mechanisms of action. CSFs stimulate hematopoietic cell proliferation and modulate immune responses through cytokine regulation, representing a fundamental change in therapeutic parameters that enables improvement in pre-existing disability beyond the 30-50% relapse reduction achieved by conventional treatments
2Reliability
If colony stimulating factors are administered to stimulate hematopoietic cell proliferation and modulate immune responses, then therapeutic benefits are achieved in demyelinating diseases, but the mechanism differs fundamentally from traditional anti-inflammatory approaches
Solution Approach 1:
The patent employs colony stimulating factors as intermediary substances that mediate between hematopoietic cell proliferation and immune response modulation. CSFs act as biological mediators that stimulate the production and differentiation of blood cells while simultaneously regulating immune system activity, providing a bridge between hematological and immunological mechanisms to treat demyelinating diseases
Data Source
AI summary
A method for treating demyelinating central nervous system diseases in a subject that comprises administering to the subject a composition comprising a therapeutically active amount of colony stimulating factor or CSF-like ligand. In a preferred embodiment of the present invention, the CSF is a GM-CSF. In a most preferred embodiment of the present invention, CSF is sargramostim.